Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
Aclarion published its Q3 2026 CEO shareholder letter reporting 85% year-over-year scan volume growth in the quarter and 117% growth for the first nine months of 2026. The clinical program advanced with the CLARITY trial expanded to eleven sites under revised enrollment criteria meant to speed recruitment, while the European Spine Journal published peer-reviewed data supporting MRS as an alternative to provocative discography.
Key figures
- Cash
- 14200000
- Runway
- into the second half of 2027
- Clarity sites
- 11
- Clarity patients
- 300
- Scan volume growth q3 yoy
- 85%
- Scan volume growth nine month yoy
- 117%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.